Quick Answer
LEMAITRE VASCULAR INC reported Research And Development Expense of $14.14 million for the year ending 2025.
- LEMAITRE VASCULAR INC showed a decrease of -9.7% in Research And Development Expense from 2024 to 2025.
- This data is from LEMAITRE VASCULAR INC's annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2009 to 2025 (17 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 17 years of available data (2009 to 2025), LEMAITRE VASCULAR INC's Research And Development Expense has grown by 139.2%.
- Historical annual values: Fiscal year 2025: $14.14 million | Fiscal year 2024: $15.65 million | Fiscal year 2023: $16.97 million | Fiscal year 2022: $13.29 million | Fiscal year 2021: $11.80 million | Fiscal year 2020: $10.10 million | Fiscal year 2019: $9.28 million | Fiscal year 2018: $8.20 million | Fiscal year 2017: $6.64 million | Fiscal year 2016: $6.14 million | Fiscal year 2015: $5.48 million | Fiscal year 2014: $4.67 million | Fiscal year 2013: $5.24 million | Fiscal year 2012: $5.09 million | Fiscal year 2011: $4.43 million | Fiscal year 2010: $5.49 million | Fiscal year 2009: $5.91 million.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: